Free Daily Podcast Summary
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders: Daily Summaries Delivered
by David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist
The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error. Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials. Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies. This podcast is for you if: You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources What you will learn: CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma. Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 4 days ago21 min
288: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 2
Manufacturability challenges in biotech are becoming more complex as therapies become more potent, formats diversify, and timelines compress across the industry. On this episode, David Brühlmann sits down with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. Sigma brings deep expertise in early-stage CMC decision-making and has guided countless programs—from upstart startups to established pipelines—through the traps and trade-offs of process development. Her ground-fl...
- 6 days ago17 min
287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1
A breakthrough in drug discovery can be derailed in an instant if manufacturability is left as an afterthought. Too many biotech programs hit bottlenecks at scale-up because key decisions in cell line and process development get kicked down the road. On the Smart Biotech Scientist Podcast, David Brühlmann spoke with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. She’s spent 25+ years converting early-stage discoveries into commercial biomanufacturing success and she’...
- 1 weeks ago17 min
286: Why Your Dormant Omics Data Is Worth More Than the Data You'll Generate Next with Nathan Lewis - Part 2
What does it take to crack the code of protein production and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers? Biotech’s ambitions are often limited not by vision, but by the real-world bottlenecks of host cell lines and the unpredictability of post-translational modifications. Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biolo...
- 1 weeks ago30 min
285: Why Your Dormant Omics Data Is Worth More Than the Data You'll Generate Next with Nathan Lewis - Part 1
Dormant omics data are a goldmine for CMC innovation waiting to be unlocked. But legacy structures, poor annotation, and spreadsheet chaos hold most biotech teams back from the real breakthroughs. Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has a clear message: actionable data is now within reach thanks to hybrid modeling, advanced study design, ...
- 2 weeks ago20 min
284: Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection with Kent Rapp - Part 2
“Does DNA barcoding actually work?” It's the first question Kent Rapp hears from prospective customers when he pitches Biolinco's DNA barcoding platform. By his own admission, the technology can sound too good to be true. In Part 2 of this conversation, Kent rejoins the Smart Biotech Scientist Podcast to address that skepticism head-on, unpack how subclone variability and bispecific antibody purity concerns shape customer trust, and share what it actually took to move Biolinco from a Johns Ho...
- 2 weeks ago21 min
283: Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection with Kent Rapp - Part 1
What if the bottleneck in cell line development isn’t how many clones you screen, but how you track them? Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability. But too often, the “perfect” clone in a 96-well plate turns into a dud when it reaches the bioreactor. That disconnect costs time, money, and promising therapies. This week, host David Brühlmann welcomes Kent Rapp, Co-founder and CEO of B...
- 3 weeks ago19 min
282: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar - Part 2
Your active ingredient is the nucleic acid. So why does a proteolipid vehicle filing include viral clearance studies, stability data and full characterisation of a membrane protein that is not the drug? Because that protein sits on the particle surface, and a component nobody has filed before is the agency's problem regardless of what you call it. Proteolipid vehicles (PLVs), the platform Jitendra Kumar works on as Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals,...
- 3 weeks ago19 min
281: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar - Part 1
Gene therapy only works if the cargo reaches the right cells intact. Adeno-associated viruses (AAV) and lipid nanoparticles have carried the field this far, but both share a constraint: the particle is taken up into an endosome, and the payload has to escape that compartment before it is degraded. Endosomal escape is where a large share of the dose is lost, and it is why delivery, not the genetic construct, is usually the thing that limits the therapy. Lipid nanoparticles carry a second const...
About Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error. Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials. Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies. This podcast is for you if: You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources What you will learn: CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma. Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders daily summary?
It's a free AI-powered email that summarizes new episodes of Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders release new episodes?
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders publishes every few days. Our AI generates a summary within hours of each new episode.
What topics does Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders cover?
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.